The Investor
10 Sep 2026, 15:57
Johnson & Johnson Receives CE Mark for New ACUVUE OASYS MAX Reusable Contact Lenses
Johnson & Johnson has received CE Marking for ACUVUE OASYS MAX 2-Week, expanding its ACUVUE portfolio with a new reusable contact lens designed to provide comfort and visual clarity throughout a two-week wear cycle. The product is expected to launch in select European markets later this year, followed by a broader rollout in 2027 and 2028.
The new lens incorporates the company’s OptiBlue Light Filter, which filters at least 60% of blue-violet light, along with TearStable Technology designed to retain moisture and Class 1 UV blocking. Johnson & Johnson is positioning the product for consumers facing increased screen exposure and demanding visual environments.
The company said 99% of existing ACUVUE OASYS 2-Week users participating in clinical testing were successfully refitted into the new lens using the same power, base curve and diameter.
The CE Mark clears ACUVUE OASYS MAX 2-Week for European markets. The product has not been approved by the U.S. Food and Drug Administration and is currently unavailable for sale in the United States.
Johnson & Johnson has received CE Marking for ACUVUE OASYS MAX 2-Week, expanding its ACUVUE portfolio with a new reusable contact lens designed to provide comfort and visual clarity throughout a two-week wear cycle. The product is expected to launch in select European markets later this year, followed by a broader rollout in 2027 and 2028.
The new lens incorporates the company’s OptiBlue Light Filter, which filters at least 60% of blue-violet light, along with TearStable Technology designed to retain moisture and Class 1 UV blocking. Johnson & Johnson is positioning the product for consumers facing increased screen exposure and demanding visual environments.
The company said 99% of existing ACUVUE OASYS 2-Week users participating in clinical testing were successfully refitted into the new lens using the same power, base curve and diameter.
The CE Mark clears ACUVUE OASYS MAX 2-Week for European markets. The product has not been approved by the U.S. Food and Drug Administration and is currently unavailable for sale in the United States.
